Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
M.D. Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Johnson & Johnson Enterprise Innovation Inc.
Janssen Research & Development, LLC
University of Pittsburgh
Royal Marsden NHS Foundation Trust
Genmab
Seagen Inc.
Seagen Inc.
NRG Oncology
Eastern Cooperative Oncology Group
H. Lee Moffitt Cancer Center and Research Institute
Memorial Sloan Kettering Cancer Center
National Institutes of Health Clinical Center (CC)
University of Cincinnati
Canadian Cancer Trials Group
Ohio State University Comprehensive Cancer Center
AstraZeneca
Eastern Cooperative Oncology Group
UNC Lineberger Comprehensive Cancer Center
M.D. Anderson Cancer Center
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
University of Michigan Rogel Cancer Center
M.D. Anderson Cancer Center
Universität des Saarlandes
Eastern Cooperative Oncology Group
R-Pharm
R-Pharm
UNC Lineberger Comprehensive Cancer Center
University of Florida
Institut Claudius Regaud
University of Miami
Sir Run Run Shaw Hospital
Merck Sharp & Dohme LLC
Massachusetts General Hospital
UNC Lineberger Comprehensive Cancer Center
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Sun Yat-sen University
Washington University School of Medicine
Radiation Therapy Oncology Group
Rigshospitalet, Denmark
Washington University School of Medicine
Inhibrx Biosciences, Inc
M.D. Anderson Cancer Center
National Cancer Institute (NCI)